Alder Biopharmaceuticals Inc (ALDR) is Trading Higher on Unusual Volume for January 14

Equities Staff |

Alder Biopharmaceuticals Inc (ALDR) experienced unusually high volume on Jan. 14, as the stock gained 10.81% to a closing price of $28.87. The stock saw 923,057 shares trade hands over the course of the day on 7,934 trades. Given that the stock’s average daily volume over the last month has been 503,011 shares a day, this represents a pretty substantial spike over the norm.

Alder Biopharmaceuticals Inc has a P/B ratio of 3.06. The stock has traded between $54.90 and $22.23 over the last 52-weeks, its 50-day SMA is now $34.70, and its 200-day SMA $37.21.

Alder BioPharmaceuticals Inc is a clinical-stage bio-pharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.

Headquartered in Bothell, WA, Alder Biopharmaceuticals Inc has 87 employees and is currently under the leadership of CEO Randall C. Schatzman.

For a complete fundamental analysis analysis of Alder Biopharmaceuticals Inc, check out’s Stock Valuation Analysis report for ALDR. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…